AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01193660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Umbilical Cord Blood
Description: Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
Study NCT04058392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camu Camu Capsules
Description: Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study
Study NCT01193660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Umbilical Cord Blood
Description: Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
Study NCT01193660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Erythropoietin
Description: Placebo Erythropoietin containing Normal Saline
Study NCT00372203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound Guided Transthoracic Needle Biopsy
Description: Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
Study NCT01279473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study NCT02503007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02503007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB-FA
Study NCT03920410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serotonergic stimulation
Description: Increase of serotonergic activity by a single oral administration of 10 mg Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI), packed in a coloured hydroxypropylmethylcellulose capsule.
Study NCT03920410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no serotonergic stimulation
Description: Oral administration of a placebo. The placebo will consist of a coloured hydroxypropylmethylcellulose capsule filled with microcrystalline cellulose.
Study NCT01854203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inductive chemotherapy + concurrent cisplatin and IMRT
Description: Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.
Study NCT01854203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inductive chemotherapy + IMRT
Description: Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
Study NCT04953429 — intervention group
Intervention type: BEHAVIORAL
Intervention: workload
Description: Mental needs, physical needs, time needs, self performance, effort, frustration, technical autonomy, decision-making autonomy and work needs of nursing work
Study NCT02725411 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for tanezumab
Description: Subcutaneous injection of the placebo every 8 weeks for 56 weeks
Study NCT01504711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant dimeglumine
Description: Given IV
Study NCT04132505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT04132505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO
Study NCT03969329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe
Study NCT04398459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Each recruited subject will accept Ibrutinib treatment.
Study NCT06673927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139
Description: Single oral dose, 2mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg
Study NCT06673927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139
Description: Multiple Dosing ，Each oral dose of 10 mg，20 mg，40 mg or 60 mg
Study NCT06673927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administration
Study NCT02547948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeting CAR T Cells infusion
Description: CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
Study NCT02428608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DWP-450 (Botulinum purified neurotoxin, Type A)
Description: Botulinum toxin, Type A
Study NCT00949273 — intervention group
Intervention type: PROCEDURE
Intervention: cylindrical abdominoperineal resection
Description: Extended abdominoperineal resection with human acellular dermal matrix reconstruction of the pelvic floor for rectal cancer
Study NCT00772473 — intervention group
Intervention type: OTHER
Intervention: subjects personal triptan
Description: Subjects will treat 1 migraine attack with their usual triptan
Study NCT03835104 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRP point-of-care testing
Description: CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
Study NCT02361749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal Myectomy
Description: Longitudinal anal myectomy will be performed under general anesthesia as a day case.
Study NCT02597842 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Description: Electric stimulation was given through electrode attached to specific acupoints
Study NCT02597842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Description: Electric stimulation was given through electrode attached to specific acupoints
Study NCT03338387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Acipimox
Study NCT03338387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Other Names: Placebo (for Olbetam)
Study NCT03909763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine plus danazol
Description: Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks
Study NCT00520676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2, IV, q 21 days x 6 cycles maximum
Study NCT00520676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m\^2, IV, q 21 days x 6 cycles maximum
Study NCT00520676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum
Study NCT00520676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum
Study NCT01011920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
Study NCT03835104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP point-of-care testing
Description: CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
Study NCT01011920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
Study NCT01011920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 conventional infusion on day - 5 \& 0 every 3 weeks for a maximum of 4 cycles
Study NCT01011920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 \& -4
Study NCT01011920 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
Study NCT01011920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
Study NCT01011920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APBSCT
Description: Autologous peripheral blood stem cell transplant (APBSCT)
Study NCT06673719 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-pertechnetate SPECT/CT
Description: This procedure is similar to standard Meckel's diverticulum scan, with the addition of SPECT/CT acquisition to measure gastric volume.
Study NCT06673719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined High-Resolution Manometry-Nutrient Drink Test
Description: Proximal gastric high-resolution manometry was done concurrently with nutrient drink test to measure proximal gastric function.
Study NCT02940522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Study NCT04439279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study NCT03598829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tryptase, Serum test
Description: Blood draw lab test which measures concentration of Tryptase in the sample. Tryptase is the one of the primary secretions of active mast cells and is used as a measure of inflammatory activity. Normal Reference Value: \&lt;11.5 ng/mL
Study NCT00997061 — intervention group
Intervention type: DRUG
Intervention: HYCAMTIN
Description: Observing patients on HYCAMTIN and other drugs for SCLC.
Study NCT06624345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Patients in the IMT group received the intervention using a threshold loading device set at a pressure range of 5-39 cmH₂O. They were instructed to perform six sets of five breaths, totaling 30 breaths, twice daily for six weeks. Additionally, the aerobic exercise regimen included upper limb exercises (raising arms without resistance), a lower limb stepping warm-up, and a walking routine consisting of 5 minutes of slow walking, 2 minutes of brisk walking, and another 5 minutes of slow walking, for a total of 30 minutes per day.
Study NCT06624345 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Subjects received routine care.
Study NCT04178005 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cladribine
Description: All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI
Study NCT04581577 — intervention group
Intervention type: OTHER
Intervention: Semi-structured telephone questionnaire
Description: Semi-structured telephone questionnaire
Study NCT02940522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Study NCT01763658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antox tablets(Mepaco)
Description: effect of antioxidant on disease outcome
Study NCT01763658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drug therapy for ITP
Description: drugs will be selected according to ASH,2011 guidelines
Study NCT01763658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: drug therapy for ITP
Description: drugs will be selected according to ASH,2011 guidelines
Study NCT03935737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Full Dose Chest X-Ray
Description: Full dose X ray at Day 1
Study NCT03935737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Low Dose Chest X-Ray
Description: Low dose X ray within 3 months from full dose
Study NCT05341934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluative Conditionning Task
Description: A word will appear in one of the four quadrants on the computer screen. They will have to answer the word as quickly as possible by pressing the space bar. They will also be told that an image will be displayed briefly (400 ms) in the same quadrant by pressing the answer key. This procedure will be repeated for 120 trials: 30 trials with alcohol-related Conditional Stimulus (CS), 30 trials with CS related to non-alcoholic beverages and 60 trials with the CS of filling. The CS referring to alcohol will be the words Beer, Wine ...; The CS referring to soft drinks will be the words Coca-Cola, Fanta... and Filling CS referring to vegetables and fruits will be: Apple, Banana...In experimental conditions, alcohol-related CS will be followed by negative Unconditional Stimuli (US) (images from the International Affective Picture System (Lang, Bradley, \& Cuthbert, 1997)), CS referring to soft drinks linked to positive images and CS referring to fruits and vegetables will be linked to neutral US.
Study NCT05341934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Evaluative Conditionning Task
Description: A word will appear in one of the four quadrants on the computer screen. They will have to answer the word as quickly as possible by pressing the space bar. They will also be told that an image will be displayed briefly (400 ms) in the same quadrant by pressing the answer key. This procedure will be repeated for 120 trials: 30 trials with alcohol-related Conditional Stimulus (CS), 30 trials with CS related to non-alcoholic beverages and 60 trials with the CS of filling. The CS referring to alcohol will be the words Beer, Wine ...; The CS referring to soft drinks will be the words Coca-Cola, Fanta... and Filling CS referring to vegetables and fruits will be: Apple, Banana...In experimental conditions, alcohol-related CS will be followed by negative Unconditional Stimuli (US) (images from the International Affective Picture System (Lang, Bradley, \& Cuthbert, 1997)), CS referring to soft drinks linked to positive images and CS referring to fruits and vegetables will be linked to neutral US.
Study NCT03566511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
Study NCT03033134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BSJ003W
Description: BSJ003W implant
Study NCT03566511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
Study NCT00654641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound closure
Description: Applying negative pressure to primary wound closure
Study NCT00654641 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound closure
Description: Standard wound closure
Study NCT02257437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LNS snack
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
Study NCT02257437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS snack
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
Study NCT02257437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn-soy blend ++ (CSB++)
Description: Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
Study NCT02257437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn-soy blend ++ (CSB++)
Description: Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
Study NCT02257437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sprinkles
Description: Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
Study NCT02257437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles
Description: Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia Chrysanthemi
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT02257437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LNS + borbor
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Study NCT02723994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Study NCT03631693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simplified papilla preservation flap
Description: The simplified papilla preservation flap (SPPF) surgery is a conservative surgical procedure aimed at the preservation of the tissues between the teeth providing access for the debridement of the root surface in sites with residual pockets.
Study NCT03631693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resective periodontal flap with osseous recontouring
Description: The Resective periodontal flap with osseous recontouring (RPFO) is a surgical procedure that achieves predictable pocket depth reduction by soft and hard tissue resection to obtain a more convenient soft and hard tissue architecture for oral hygiene.
Study NCT04187404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EO2401
Description: Multiple dose of EO2401
Study NCT04187404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Multiple dose of nivolumab
Study NCT03306810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AG service
Description: The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
Study NCT04187404 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Multiple dose of nivolumab
Study NCT04066829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default setting intervention
Description: The new default settings will be implemented only for patients in the experimental arm.
Study NCT03995472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1501
Description: Administered subcutaneously
Study NCT03995472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: Administered intravenously
Study NCT02806973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.
Study NCT00775671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
Study NCT02257437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS + borbor
Description: Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).